查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1138307

阿苯达唑驱虫剂全球市场2022-2029

Global Albendazole Anthelmintic Drug Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 190 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

阿苯达唑驱虫药治疗蠕虫病的需求扩大

Celrhisis 被称为人类和其他动物的一种大型寄生虫病，其中大部分身体都被称为蠕虫的寄生虫侵染。由于蛔虫、钩虫、鞭虫等，流行率上升预计将推动驱虫药市场。作为回报，预计全球经济规模将有所改善。据世卫组织称，截至 2020 年 3 月，全世界有近 15 亿人遭受土传蠕虫感染。这个数字占全球人口的 24%。蛔虫（蛔虫）、Tritula（鞭虫）、美洲钩虫和十二指肠钩虫是增加疾病负担的主要物种（钩虫）。根据世卫组织的资料，2020年3月，撒哈拉以南非洲、美洲、中国和亚洲国家的土传蠕虫感染分布较高。例如，国家驱虫日是印度卫生和家庭福利部政府为使该国无虫害而做出的一项重大努力。根据世界卫生组织的数据，印度有 2.41 亿 1 至 14 岁的儿童感染肠道寄生虫的风险很高，这些寄生虫是寄生虫。预计政府还将就提高认识活动和根除蠕虫病提出建议。

另一方面，阿苯达唑驱虫药的副作用，如头痛、颈部僵硬、对光的敏感性增加、精神错乱和发烧，可能会限制市场份额。此外，阿苯达唑可能会增加出血和感染的风险。

全球阿苯达唑驱虫药市场报告将提供大约 51 个市场数据表、45 个数字和 190 页

目录

第一章调查方法及范围

  • 调查方法
  • 市场范围

第 2 章主要趋势和发展

第 3 章执行摘要

  • 按类型划分的市场细分
  • 按应用划分的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
    • 约束因素
    • 商机
  • 影响分析

第五章行业分析

  • 波特五力分析
  • 供应链分析
  • PEST 分析
  • 定价分析
  • 报销分析
  • 监管分析
  • 未满足的需求
  • 专利趋势

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措

第 7 章按类型

  • 药片
  • 胶囊
  • 其他

第 8 章最终用户

  • 人类
  • 兽药

第 9 章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 意大利
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 10 章竞争格局

  • 竞争场景
  • 竞争对手战略分析
  • 市场情况/份额分析
  • 併购分析

第 11 章公司简介

  • GlaxoSmithKline
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Fredun Pharmaceuticals Ltd
  • Sequent Scientific
  • Huazhong Pharmaceutical
  • Zhongjia Pharmaceutical
  • Jiangsu Qihui
  • Salius Pharma
  • Lasa Supergenerics Limited
  • K.A. Malle Pharmaceuticals
  • Supharma Chem

第12章 DataM

简介目录
Product Code: DMPH3121

Market Overview

Albendazole anthelmintic drug market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 6.5% during the forecast period (2022-2029).

Albendazole, also known as albendazole, is an anthelmintic drug. It inhibits the production or replication of new insect larvae (worms) in the body. It is used to combat inflammatory diseases from worms like pork wire and dog tapestry. For various purposes, albendazole can be used in humans and livestock. The capillary disease is caused by Capillary pelican (dogs and cats), and C is used in poultry. Cati Felis (cats). Capillary bladders infect, so they are sometimes referred to as bladder worms. With albendazole. Due to growing neurocysticercosis cases, the demand for albendazole drugs will expand dramatically in the coming years (infection caused by the pork tapeworm in the muscles, brain, and eyes that may cause seizures, brain swelling, and vision problems).

Market Dynamics: Growing demand Albendazole Anthelmintic Drug in the treatment of Helmonthasis

Helmonthasis, also known as worm infection, is a human and other animal macroparasite disease that includes parasite worms in most of the body, known as helminths (helminths). A rise in the prevalence is expected to drive the market for anthelmintic medicine caused by roundworm, hookworm, whipworm and other worms. In exchange, the size of the global economy is projected to improve. According to the WHO, nearly 1.5 billion people worldwide have suffered from soil-borne helminth infection as of March 2020. 24 per cent of the global human population accounts for this figure. Ascaris lumbricoides (roundworms), trichuriasis trichiura (whipworms), necator americanus, and ancylostoma duodenale are major species that raise the disease burden (hookworms). According to WHO info, soil-transmitted helminth infection distribution in Sub-Saharan Africa, the Americas, China and countries in Asia was higher in March 2020. The National Deworming Day, for example, is a big effort by the Government of India's Ministry of Health and Family Welfare to make the nation worm-free. In India, 241 million children aged 1 to 14 years are at higher risk of parasitic intestinal worms, according to the WHO. The government is also expected to establish recommendations for awareness-raising and the eradication of helminth infection.

On the other hand, albendazole anthelmintic drug's side effects, such as headache, neck stiffness, increased sensitivity to light, confusion, and fever, may act as restraint of the market share. Further, Albendazole can increase your risk of bleeding or infection.

Market Segmentation: The tablet albendazole anthelmintic drug segment is projected to be the market's dominant segment during the forecast period

The tablets segment accounts for the largest market share of the global Albendazole Anthelmintic Drug market and is projected to rise during the forecast period at its highest CAGR. The category of tablets and powders is growing primarily because of ease of use and relatively better absorption

Different prevention steps for the management of parasites in animals are being introduced. Veterinarians rely on anthelmintic drugs to protect the animals' health as vaccines are not readily available, and better vaccines have to be developed. Companies take advantage of value capturing opportunities for improved animal health through increased available macrocyclic benzimidazoles and tetrahydro pyrimidines on the anthelmintic drugs market.

Geographical Penetration: North America is the dominating region during the forecast period

In North America, major research and development players will account for the significant share of global albendazole demand for medicines. The USA, for example. The Food and Drug Administration authorized the Cipla Abbreviated New Medication Request for Albendazole Tablets. Further, major players in the region are adopting the product launch to increase the product portfolio and gain competitive market share. Moreover, the demand for albendazole drugs in Asia-Pacific is expected to develop rapidly in the timeframe predicted, as the prevalence of helminthic infection is growing and increasing.

Competitive Landscape:

The albendazole anthelmintic drug market is moderately competitive, owing to major market players in the key regions such as the US, China, India and others. The key albendazole anthelmintic drug players contributing to the growth of the global market include GlaxoSmithKline, Fredun Pharmaceuticals Ltd, Sequent Scientific, Huazhong Pharmaceutical, Zhongjia Pharmaceutical, Jiangsu Qihui, Salius Pharma, Lasa Supergenerics Limited, K.A. Malle Pharmaceuticals, Supharma Chem, among others. The major players are adopting new product launch and expansion strategies for global growth in the albendazole anthelmintic drug market. In June 2020, Pharma major Lupin announced that it has received approval for its Albendazole Tablets USP, 200 mg, from the U.S. FDA, to market a generic equivalent of Albenza Tablets, 200 mg, of Impax Laboratories Inc. In April 2021, Dr. Reddy's Laboratories along with its subsidiaries announced the launch of Albendazole Tablets, USP, a therapeutic equivalent generic version of Albenza Tablets, approved by the U.S. Food and Drug Administration (USFDA).

COVID-19 Impact: Positive impact on the global Albendazol Anthelmintic Drug market

With the continuing breakout of coronavirus COVID-19, the unprecedented need for medications to tackle the novel infection has been intensified. As a result, AI, Gero, is recognized as a global expert in AI-driven drug developments and validating promising anthelmintic drug therapy potentials for COVID-19. As a result, the treatment of coronavirus in patients with niclosamide has proven to be successful. It has been approved in the U.S., Italy, France, and a few other countries where active COVID-19 patients are high. With the authorization of niclosamide, the effective use of AI-driven drug development approaches to build upon revenue-generating opportunities in industries on the anthelmintics market increases. Anthelmintic drug market firms are working to carry out clinical trials of existing therapeutic drugs that can be effective for treating coronavirus, which has further led to the demand for albendazole anthelmintic drug.

The global albendazole anthelmintic drug market report would provide an access to approximately 51 market data tables, 45 figures and 190 pages

Table of Contents

Scope and Methodology

  • 1.1. Research Methodology
  • 1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market impacting factors
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
  • 4.2. Impact analysis

5. Industry Analysis

  • 5.1. Porter's five forces analysis
  • 5.2. Supply Chain analysis
  • 5.3. PEST Analysis
  • 5.4. Pricing Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Unmet Needs
  • 5.8. Patent Trends

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Type Segment
    • 7.1.2. Market attractiveness index, By Type Segment
  • 7.2. Tablet*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 7.3. Capsule
  • 7.4. Others

8. By End-User

  • 8.1. Introduction
    • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By Application Segment
    • 8.1.2. Market attractiveness index, By Application Segment
  • 8.2. Human*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 8.3. Veterinary

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key region-specific dynamics
    • 9.2.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
    • 9.2.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. South America
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
    • 9.3.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.3.5.1. Brazil
      • 9.3.5.2. Argentina
      • 9.3.5.3. Rest of South America
  • 9.4. Europe
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.4.5.1. Germany
      • 9.4.5.2. U.K.
      • 9.4.5.3. France
      • 9.4.5.4. Spain
      • 9.4.5.5. Italy
      • 9.4.5.6. Rest of Europe
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application

10. Competitive Landscape

  • 10.1. Competitive scenario
  • 10.2. Competitor strategy analysis
  • 10.3. Market positioning/share analysis
  • 10.4. Mergers and acquisitions analysis

11. Company Profiles

  • 11.1. GlaxoSmithKline*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Fredun Pharmaceuticals Ltd
  • 11.3. Sequent Scientific
  • 11.4. Huazhong Pharmaceutical
  • 11.5. Zhongjia Pharmaceutical
  • 11.6. Jiangsu Qihui
  • 11.7. Salius Pharma
  • 11.8. Lasa Supergenerics Limited
  • 11.9. K.A. Malle Pharmaceuticals
  • 11.10. Supharma Chem
  • List not Exhaustive*

12. DataM

  • 12.1. Appendix
  • 12.2. About us and services
  • 12.3. Contact us